The impact of G‐protein‐coupled receptor hetero‐oligomerization on function and pharmacology
暂无分享,去创建一个
M. Scarselli | G. Corsini | R. Maggio | Marco Scarselli | Roberto Maggio | Francesca Novi | Giovanni U Corsini | F. Novi
[1] Horst Vogel,et al. Oligomerization of the α1a- and α1b-Adrenergic Receptor Subtypes , 2003, Journal of Biological Chemistry.
[2] M. Millan,et al. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole , 2003, Journal of neurochemistry.
[3] P. Sigler,et al. The 2.8 A crystal structure of visual arrestin: a model for arrestin's regulation. , 1999, Cell.
[4] M. Scarselli,et al. The Paired Activation of the Two Components of the Muscarinic M3 Receptor Dimer Is Required for Induction of ERK1/2 Phosphorylation* , 2004, Journal of Biological Chemistry.
[5] P. Sokoloff,et al. D2/D3 Dopamine Receptor Heterodimers Exhibit Unique Functional Properties* , 2001, The Journal of Biological Chemistry.
[6] H. Vogel,et al. Oligomerization of the alpha 1a- and alpha 1b-adrenergic receptor subtypes. Potential implications in receptor internalization. , 2003, The Journal of biological chemistry.
[7] R. Lefkowitz. Historical review: a brief history and personal retrospective of seven-transmembrane receptors. , 2004, Trends in pharmacological sciences.
[8] Mario Mellado,et al. Chemokine receptor homo‐ or heterodimerization activates distinct signaling pathways , 2001, The EMBO journal.
[9] M. Bouvier,et al. Hetero-oligomerization between beta2- and beta3-adrenergic receptors generates a beta-adrenergic signaling unit with distinct functional properties. , 2004, The Journal of biological chemistry.
[10] Graeme Milligan,et al. Homo- and hetero-oligomeric interactions between G-protein-coupled receptors in living cells monitored by two variants of bioluminescence resonance energy transfer (BRET): hetero-oligomers between receptor subtypes form more efficiently than between less closely related sequences. , 2002, The Biochemical journal.
[11] G. Büldt,et al. X-ray crystal structure of arrestin from bovine rod outer segments , 1998, Nature.
[12] S. Schulz,et al. Heterodimerization of Substance P and μ-Opioid Receptors Regulates Receptor Trafficking and Resensitization* , 2003, Journal of Biological Chemistry.
[13] Lakshmi A. Devi,et al. G-protein-coupled receptor heterodimerization modulates receptor function , 1999, Nature.
[14] F. Giorgi,et al. Paired Activation of Two Components within Muscarinic M3 Receptor Dimers Is Required for Recruitment of β-Arrestin-1 to the Plasma Membrane* , 2005, Journal of Biological Chemistry.
[15] B. O'dowd,et al. Dopamine D1 and D2 Receptor Co-activation Generates a Novel Phospholipase C-mediated Calcium Signal* , 2004, Journal of Biological Chemistry.
[16] R. Lefkowitz,et al. β-Arrestin 2: A Receptor-Regulated MAPK Scaffold for the Activation of JNK3 , 2000 .
[17] R. Lefkowitz,et al. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. , 2002, Journal of cell science.
[18] Luigi F Agnati,et al. Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons , 2003, Pharmacological Reviews.
[19] S. Allouche,et al. Differential G-protein activation by alkaloid and peptide opioid agonists in the human neuroblastoma cell line SK-N-BE. , 1999, The Biochemical journal.
[20] Krzysztof Palczewski,et al. Organization of the G Protein-coupled Receptors Rhodopsin and Opsin in Native Membranes* , 2003, Journal of Biological Chemistry.
[21] J. W. Wells,et al. Cooperativity and oligomeric status of cardiac muscarinic cholinergic receptors. , 2002, Biochemistry.
[22] H. Lother,et al. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration , 2000, Nature.
[23] E. Lakatta,et al. Beta 1/beta 2-adrenergic receptor heterodimerization regulates beta 2-adrenergic receptor internalization and ERK signaling efficacy. , 2002, The Journal of biological chemistry.
[24] L. Miller,et al. Heterodimerization of Type A and B Cholecystokinin Receptors Enhance Signaling and Promote Cell Growth* , 2003, Journal of Biological Chemistry.
[25] P. Sigler,et al. A Model for Arrestin’s Regulation: The 2.8 Å Crystal Structure of Visual Arrestin , 1999, Cell.
[26] R. Mullins,et al. β-Arrestin–Dependent Endocytosis of Proteinase-Activated Receptor 2 Is Required for Intracellular Targeting of Activated Erk1/2 , 2000, The Journal of cell biology.
[27] Ramesh C. Patel,et al. The Role of Subtype-specific Ligand Binding and the C-tail Domain in Dimer Formation of Human Somatostatin Receptors* , 2004, Journal of Biological Chemistry.
[28] Pierre Corvol,et al. Polar Residues in the Transmembrane Domains of the Type 1 Angiotensin II Receptor Are Required for Binding and Coupling , 1996, The Journal of Biological Chemistry.
[29] E I Canela,et al. Dopamine D1 and adenosine A1 receptors form functionally interacting heteromeric complexes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[30] P. Sigler,et al. Crystal structure of beta-arrestin at 1.9 A: possible mechanism of receptor binding and membrane Translocation. , 2001, Structure.
[31] M. Bouvier,et al. Hetero-oligomerization between β2- and β3-Adrenergic Receptors Generates a β-Adrenergic Signaling Unit with Distinct Functional Properties* , 2004, Journal of Biological Chemistry.
[32] K. Blumer,et al. Subunits of a Yeast Oligomeric G Protein-coupled Receptor Are Activated Independently by Agonist but Function in Concert to Activate G Protein Heterotrimers* , 2004, Journal of Biological Chemistry.
[33] Joseph Parello,et al. Structure-based analysis of GPCR function: evidence for a novel pentameric assembly between the dimeric leukotriene B4 receptor BLT1 and the G-protein. , 2003, Journal of molecular biology.
[34] J. Taylor,et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. , 2002, The Journal of clinical endocrinology and metabolism.
[35] Michel Bouvier,et al. Heterodimerization of V1a and V2 vasopressin receptors determines the interaction with beta-arrestin and their trafficking patterns. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[36] David J. Daniels,et al. A Bivalent Ligand (KDN-21) Reveals Spinal δ and κ Opioid Receptors Are Organized as Heterodimers That Give Rise to δ1 and κ2 Phenotypes. Selective Targeting of δ−κ Heterodimers , 2004 .
[37] Michel Bouvier,et al. A Peptide Derived from a β2-Adrenergic Receptor Transmembrane Domain Inhibits Both Receptor Dimerization and Activation* , 1996, The Journal of Biological Chemistry.
[38] J. Banères,et al. Cooperative Conformational Changes in a G-protein-coupled Receptor Dimer, the Leukotriene B4 Receptor BLT1* , 2004, Journal of Biological Chemistry.
[39] J. Wess,et al. Coexpression studies with mutant muscarinic/adrenergic receptors provide evidence for intermolecular "cross-talk" between G-protein-linked receptors. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[40] B. Mouillac,et al. Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. , 2003, Molecular endocrinology.
[41] M. Caron,et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. , 1999, Science.
[42] L. Devi,et al. Oligomerization of opioid receptors with beta 2-adrenergic receptors: a role in trafficking and mitogen-activated protein kinase activation. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[43] R. Lefkowitz,et al. β-Arrestin Scaffolding of the ERK Cascade Enhances Cytosolic ERK Activity but Inhibits ERK-mediated Transcription following Angiotensin AT1a Receptor Stimulation* , 2002, The Journal of Biological Chemistry.
[44] Michel Bouvier,et al. Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function. , 2002, Annual review of pharmacology and toxicology.
[45] U. Kumar,et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. , 2000, Science.
[46] Graeme Milligan,et al. Domain Swapping in the Human Histamine H1 Receptor , 2004, Journal of Pharmacology and Experimental Therapeutics.
[47] N. Bunnett,et al. The proliferative and antiapoptotic effects of substance P are facilitated by formation of a beta -arrestin-dependent scaffolding complex. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[48] B. O'dowd,et al. Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. , 2000, The Journal of biological chemistry.
[49] P. Seeman,et al. Blockade of G Protein-Coupled Receptors and the Dopamine Transporter by a Transmembrane Domain Peptide: Novel Strategy for Functional Inhibition of Membrane Proteins in Vivo , 2003, Journal of Pharmacology and Experimental Therapeutics.
[50] E. Lakatta,et al. β1/β2-Adrenergic Receptor Heterodimerization Regulates β2-Adrenergic Receptor Internalization and ERK Signaling Efficacy* , 2002, The Journal of Biological Chemistry.